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Introduction 
Angina pectoris, first described by William Heberden in the Royal College of Physicians, 
London, in 1768, is chest pain of cardiac origin. Despite being a symptom, angina is a 
disease-based diagnosis (International Classification of Disease, I20). Practice guidelines use 
somewhat different terms. The nomenclature of the American guidelines includes ‘chronic 
stable angina (CSA)’ (2002) and ‘stable ischemic heart disease (SIHD)’ (2012), whereas the 
guidelines of the European Society of Cardiology (ESC, 2013) refer to ‘stable coronary 
artery disease (SCAD)’. Thus there are multiple terms and abbreviations for SIHD and 
cohesion is lacking. 
By contrast, ‘acute coronary syndrome’ (ACS) is a unifying hierarchical term that subtends 
the distinct sub-groups of unstable angina and myocardial infarction and is used consistently 
worldwide. 
The conundrum of angina in patients with no obstructive CAD 
The established diagnostic pathways for patients with suspected angina have been 
appropriately developed to identify obstructive coronary artery disease (CAD) with a view to 
evidence-based treatment. In recent years, however, multiple clinical studies have disclosed 
that more than one third of symptomatic patients do not have obstructive CAD1.  Further, 
ischemia may be substantial in this subgroup and the prognosis is not benign2. 
Exclusion of obstructive CAD in a patient with angina presents a conundrum. Angina without 
obstructive CAD may be frustrating for the patient and the clinician, and in the absence of a 
unifying diagnosis, treatment becomes empirical and potentially sub-optimal. The lack of 
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evidence from randomized controlled clinical trials in this sub-group underpins the 
heterogeneity in management.  
Sex association with ischemia and no obstructive coronary disease and prognosis 
‘Syndrome X’ is a historical term stigmatized by its associations with female sex, obesity, 
and psychology, leading to therapeutic nihilism in the minds of some clinicians. Although 
reductions in mortality attributable to coronary heart disease (CHD) have been observed in 
recent decades, no such decline has been observed in younger (<55 years) women3. The 
persistence of risk among younger women may be explained in part by impaired coronary 
flow reserve (CFR) rather than obstructive CAD1.  
Given this vexing state-of-affairs2,3, the recent White Paper by Bairey Merz et al1 is a 
welcome development. The authors cite a new term for the sub-group of patients with 
ischemia and no obstructive CAD (INOCA [Ischemia and No Obstructive Coronary Artery 
Disease]), the gaps in evidence and areas for future research.  
Diagnostic tests for CAD and their limitations for identifying the etiology of INOCA 
Historically, anatomical and functional tests were developed for the detection of obstructive 
CAD and validated against the coronary angiogram. Increasingly, invasive examinations 
include adjunctive measurements, such as fractional flow reserve (FFR), however, neither 
angiography nor FFR evaluate microvascular function.  
Given the clinical focus on obstructive CAD, only a minority of invasive cardiologists are 
competent in the use of interventional diagnostic procedures, including pharmacological tests 
of coronary endothelial function and vasospasm by intra-coronary administration of 
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acetylcholine and guidewire-based tests of coronary vasoreactivity (i.e. CFR) and 
microvascular resistance, respectively. This gap is underpinned by the lack of evidence from 
randomized trials that the use of such tests improves patient wellbeing and healthcare costs. 
Stress magnetic resonance imaging and positron emission tomography have diagnostic utility 
for coronary microvascular dysfunction, but as with the invasive diagnostic tests, evidence of 
patient benefits from randomized trials is lacking. 
An emerging focus on direct imaging of CAD is highlighted by the U.K. NICE guideline-95 
update (November 2016)4 which recommended CT coronary angiography (CTCA) as the first 
line diagnostic test in patients with angina but without prior CHD. NICE-95 reflects the 
results from recent trials involving CTCA. Compared with functional testing, the use of 
CTCA is associated with an increased use of evidence-based therapy and, potentially, a 
reduction in the risk of MI.  
Adoption of CTCA as a first line test in patients with chest pain is increasing worldwide. In 
the U.K., the NICE-95 update has major implications not only regarding access to CTCA, but 
also for the management of symptomatic patients without obstructive CAD, the majority of 
whom are women. Some of these patients may have microvascular or vasospastic angina and 
the exclusion of obstructive CAD by CTCA may lead to false reassurance. 
The SCOT-HEART quality of life analysis highlights this conundrum5. Symptoms and 
quality of life assessed at baseline and 6 months improved less in patients assigned to the 
CTCA-guided strategy as compared to standard care. I was a member of the Trial Steering 
Committee and this result was unexpected. One potential explanation could be false 
reassurance for those patients with INOCA, in whom angina therapy may have been 
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discontinued. This analysis refuted the hypothesis that symptoms and quality of life would 
improve with a CTCA-guided strategy and it conflicts with the NICE-95 update.  
The case for unifying terminology  
In summary, the conundrums relating to the lack of decline in CHD mortality in younger 
women, inconsistent disease nomenclature, focus on anatomical imaging, heterogeneous 
management of disease sub-groups (i.e. INOCA and related gaps in clinical evidence), 
unexpected trial results, and controversial guideline recommendations are ‘on my mind’.  
The diagnostic classifier ‘acute coronary syndrome’ is a significant term that subtends the 
distinct clinical presentations of patients with acute coronary disease. Considering SIHD and 
its disease sub-groups, there is a critical lack of a unifying high-level classifier. In my 
opinion, this gap in terminology associates with some of the issues outlined above. In the 
absence of simple, consistent nomenclature, advances in our understanding of disease 
subgroups such as INOCA, which is a current hot topic in cardiology, are less well placed for 
translation into practice. Given the focus on obstructive CAD, this gap could potentially 
enhance under-recognition and under-treatment of patients with INOCA. The term ‘acute 
coronary syndrome’ has high-level, unifying significance so it seems logical to propose the 
term ‘stable coronary syndrome’ (Figure 1). This term would sit well in the hierarchical 
classification of IHD and serve to highlight that angina is not synonymous with obstructive 
CAD and that a disorder of coronary artery function may be relevant. 
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Figure Legend 
A hierarchical nomenclature of diagnostic terms for coronary disease subgroups that cause 
ischemic heart disease.  
Stable coronary syndromes and acute coronary syndromes are second order terms that 
broadly encompass the IHD subgroups including obstructive and non-obstructive CAD and 
disorders of coronary artery function including microvascular and vasospastic angina. 
 
Key: CAD coronary artery disease; INOCA - ischemia and no obstructive coronary artery 
disease; MINOCA – myocardial infarction and no obstructive coronary artery disease; UA – 
unstable angina; NSTEMI - non-ST-segment elevation myocardial infarction; STEMI - ST-
segment elevation myocardial infarction. 
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Figure 1. 
 
